Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sun Pharmaceuticals Industries's PB Ratio or its related term are showing as below:
NSE:SUNPHARMA'
s PB Ratio Range Over the Past 10 Years
Min: 1.99 Med: 4.18 Max: 6.63
Current: 5.46
During the past 13 years, Sun Pharmaceuticals Industries's highest PB Ratio was 6.63. The lowest was 1.99. And the median was 4.18.
NSE:SUNPHARMA's PB Ratio is ranked worse than 84.19% of 917
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs NSE:SUNPHARMA: 5.46
During the past 12 months, Sun Pharmaceuticals Industries's average Book Value Per Share Growth Rate was 15.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sun Pharmaceuticals Industries was 58.40% per year. The lowest was 5.10% per year. And the median was 19.85% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sun Pharmaceuticals Industries PB Ratio Related Terms
Sun Pharmaceuticals Industries PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharmaceuticals Industries's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharmaceuticals Industries PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharmaceuticals Industries's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sun Pharmaceuticals Industries's PB Ratio falls into.
Sun Pharmaceuticals Industries PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sun Pharmaceuticals Industries (NSE:SUNPHARMA) has a PB Ratio of 5.46 as of Aug. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sun Pharmaceuticals Industries and its competitors. This is 31% above median its historical median of 4.18. Over the past decade, Sun Pharmaceuticals Industries' PB Ratio has ranged from 1.99 to 6.63. According to the industry distribution chart, Sun Pharmaceuticals Industries ranks #772 out of 917 companies in the Drug Manufacturers industry, placing it in the top 84.2%.
Is Sun Pharmaceuticals Industries' PB Ratio too high?
Sun Pharmaceuticals Industries' current PB Ratio of 5.46 is 31% above median its 10-year median of 4.18. Over the past 10 years, this metric has ranged from a low of 1.99 to a high of 6.63. The Drug Manufacturers industry median PB Ratio is 1.97. Sun Pharmaceuticals Industries' value of 5.46 is 177.2% above this industry median. Based on the distribution chart, Sun Pharmaceuticals Industries ranks #772 out of 917 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sun Pharmaceuticals Industries has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharmaceuticals Industries' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharmaceuticals Industries ranks #772 out of 917 companies for PB Ratio. This places Sun Pharmaceuticals Industries in the lower half of its industry. The industry median PB Ratio is 1.97. Sun Pharmaceuticals Industries' value of 5.46 is 177.2% above this benchmark. Historically, Sun Pharmaceuticals Industries' own PB Ratio has ranged from 1.99 to 6.63 over the past decade. While the company's 10-year median is 4.18 vs. the industry median of 1.97, Sun Pharmaceuticals Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharmaceuticals Industries's current PB Ratio of 5.46 is 177.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sun Pharmaceuticals Industries and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharmaceuticals Industries's current PB Ratio is 5.46, which is 31% above median its own 10-year median of 4.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharmaceuticals Industries stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries (NSE:SUNPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,954.66, compared to a current price of ₹1,902.40 — trading 2.7% below its estimated fair value. The current PB Ratio is 5.46, which is 31% above median its 10-year median of 4.18 and 177.2% above the Drug Manufacturers industry median of 1.97. Sun Pharmaceuticals Industries' overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sun Pharmaceuticals Industries (NSE:SUNPHARMA), the current PB Ratio is 5.46 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharmaceuticals Industries (NSE:SUNPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries stock appears to be undervalued.
The current stock price of ₹1,902.40 is trading 2.7% below its estimated GF Value™ of ₹1,954.66.
GuruFocus considers Sun Pharmaceuticals Industries to be Fairly Valued.
Key valuation signals for NSE:SUNPHARMA:
PB Ratio: 5.46 (31% above median its 10-year median of 4.18)
GF Value™: ₹1,954.66 vs. price of ₹1,902.40 (2.7% below fair value)
Industry Position: 177.2% above the Drug Manufacturers median (#772 of 917)
No single metric tells the full story. See the NSE:SUNPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company's substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
92GF Score
Get the complete analysis for NSE:SUNPHARMA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUNPHARMA has been successfully added to your 
